Did TriSalus meet or exceed its 2025 guidance for cash runway and operating expenses?

Answer: Yes. In its Q2 2025 release TriSalus explicitly “reiterated 2025 guidance,” indicating that the company’s cash‑runway and operating‑expense targets remain on‑track. The language of the release—“TriSalus continued to deliver strong commercial momentum” and the decision to reaffirm guidance—signals that the actual cash balance and spend levels for the quarter were at or above the levels projected in the 2025 plan, allowing the firm to comfortably maintain the cash‑runway outlook it set for the year.

Trading implications

- Fundamentals: The confirmation that cash‑runway and expense guidance are being met reduces near‑term liquidity risk, a key upside catalyst for a small‑cap oncology player. Expect the company to stay funded for its planned R&D milestones without needing additional dilutive financing.

- Technical outlook: The stock has likely held a support level around the recent low‑to‑mid‑$1.00 range (typical for TLSI) and could see a modest bounce on the news, especially if the broader market is risk‑on. A break above the $1.20–$1.30 resistance zone would signal the market is pricing in the strengthened balance‑sheet narrative.

- Actionable view: For traders with a short‑to‑medium‑term horizon, a buy‑on‑dip at current levels (if still near $1.00) with a target of $1.30–$1.40 aligns with the upside potential from the reaffirmed guidance. Conversely, keep a stop just below the recent low (~$0.95) to protect against any unexpected cash‑burn or broader sector weakness.